Public advisory - Rhinaris Nasal Mist: One lot recalled due to risk of microbial growth which may lead to infection
OTTAWA, ON, July 7, 2023 /CNW/ -
Summary
Product: Rhinaris Nasal Mist 30 mL (lot 230391A)
Issue: Health products - Product safety
What to do: Do not use this product. Return it to your local pharmacy for proper disposal. Consult a health care professional if you have used this product and have health concerns.
Images
Affected products
Product
DIN
Lot
Expiry date
UPC
Rhinaris Nasal Mist 30 mL
02354551
230391A
31-05-2025
5760622302
Issue
The Pendopharm Division of Pharmascience Inc. is recalling one lot of Rhinaris Nasal Mist due to the risk of microbial growth. Using a product contaminated with microbes may lead to rhinosinusitis (a sinus infection). Children, pregnant people, seniors and people with weaker immune systems may be more susceptible to infection or complications from microbial contamination.
Rhinaris Nasal Mist is an over-the-counter drug used to moisturize and lubricate dry nasal passages in adults and children at least two years of age.
The company's testing showed that the preservative in the product may not be as effective as expected, which could lead to an increased risk of growth of microbes such as molds or bacteria over time if they are introduced into the product.
Although rare, rhinosinusitis can lead to more serious complications, such as nasal abscesses (a collection of pus), cellulitis (skin infection) or meningitis (infection and inflammation of the fluid and membranes surrounding the brain and spinal cord).
While the growth of other microbes may be possible, the testing showed that the preservative may not prevent the growth of a specific type of bacteria called Pseudomonas aeruginosa if it is introduced into the product. For someone whose immune system has been weakened by other serious conditions, especially cystic fibrosis, HIV/AIDS, severe lung disease, cancer, diabetes, or burns, Pseudomonas aeruginosa can cause serious infections including pneumonia, bone infections, urinary tract infections, gastrointestinal infections, meningitis, and blood infections.
What you should do
Do not use this product. Return it to your local pharmacy for proper disposal.
Consult a health care professional if you have used this product and have health concerns.
Contact Pendopharm Division of Pharmascience Inc. by calling 1-888-550-6060 or emailing [email protected] if you have questions about this recall.
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...
YOUR LEGAL RIGHTS MAY BE AFFECTED
There is a proposed settlement in a class-action lawsuit filed against Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, and Warner-Lambert Company LLC (collectively, "Pfizer") and Ranbaxy Inc.,...